Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
New Mexico Cancer Research Alliance
The aim of this study is to test the effect of the combination of valproate in combination with imatinib with an aim of achieving a maximal molecular response as the primary goal. Briefly, patients with CML who are taking imatinib and have been found to have a plateau in their level of the bcr-abl transcript will be eligible to participate in the study. Valproate will then be added to the imatinib, and subsequent bcr-abl transcripts will be monitored to see if the addition of valproate produced a further reduction. Patients will be monitored for efficacy and toxicity.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
All patients, 18 years of age or older, with a diagnosis of CML.
Patients must have a life expectancy of at least 12 weeks.
Patients must have an ECOG performance status of 0-2.
Patients must sign an informed consent.
Patients should have adequate hepatic function with a total bilirubin \< 2 mg/dl and SGOT or SGPT \< two times the upper limit of normal, and adequate renal function as defined by a serum creatinine \< 1.5 x upper limit of normal.
Patients with CML in chronic phase on imatinib as first line therapy who fulfill the following criteria:
The last two quantitative RT-PCR studies should be at least 3 months apart.
The patient should have received at least 9 months of imatinib since the diagnosis of CML.
The patient is tolerating imatinib without any grade 3 or greater toxicity.
You may not be if
Patients may receive no other concurrent chemotherapy or radiation therapy during this trial.
Patients who have a hypersensitivity to valproic acid, derivatives, or any component of the formulation. Patients with hepatic disease or significant impairment, or urea cycle disorders